O'Neill Maeghan, Geary James F, Agnew Dalen W, Mackenzie Charles D, Geary Timothy G
Institute of Parasitology and Centre for Host-Parasite Interactions, McGill University, Ste-Anne-de-Bellevue, QC H9X 3V9, Canada.
Department of Pathobiology and Diagnostic Investigation, Michigan State University, East Lansing, MI 48824, USA.
Int J Parasitol Drugs Drug Resist. 2015 Jul 7;5(3):135-40. doi: 10.1016/j.ijpddr.2015.06.002. eCollection 2015 Dec.
The use of a microfilaricidal drug for the control of onchocerciasis and lymphatic filariasis necessitates prolonged yearly dosing. Prospects for elimination or eradication of these diseases would be enhanced by availability of a macrofilaricidal drug. Flubendazole (FLBZ), a benzimidazole anthelmintic, is an appealing candidate macrofilaricide. FLBZ has demonstrated profound and potent macrofilaricidal effects in a number of experimental filarial rodent models and one human trial. Unfortunately, FLBZ was deemed unsatisfactory for use in mass drug administration (MDA) campaigns due to its markedly limited oral bioavailability. However, a new formulation that provided sufficient bioavailability following oral administration could render FLBZ an effective treatment for onchocerciasis and LF. This study characterized the effects of FLBZ and its reduced metabolite (FLBZ-R) on filarial nematodes in vitro to determine the exposure profile which results in demonstrable damage. Adult female Brugia malayi were exposed to varying concentrations of FLBZ or FLBZ-R (100 nM-10 μM) for up to five days, after which worms were fixed for histology. Morphological damage following exposure to FLBZ was observed prominently in the hypodermis and developing embryos at concentrations as low as 100 nM following 24 h exposure. The results indicate that damage to tissues required for reproduction and survival can be achieved at pharmacologically relevant concentrations.
使用杀微丝蚴药物来控制盘尾丝虫病和淋巴丝虫病需要每年长期给药。若有杀成虫药物,消除或根除这些疾病的前景将得到改善。氟苯达唑(FLBZ)是一种苯并咪唑驱虫药,是一种有吸引力的杀成虫候选药物。FLBZ在一些实验性丝虫啮齿动物模型和一项人体试验中已显示出显著而有效的杀成虫作用。不幸的是,由于其口服生物利用度明显有限,FLBZ被认为不适合用于大规模药物给药(MDA)活动。然而,一种口服后能提供足够生物利用度的新制剂可能会使FLBZ成为治疗盘尾丝虫病和淋巴丝虫病的有效药物。本研究对FLBZ及其还原代谢产物(FLBZ-R)在体外对丝虫线虫的作用进行了表征,以确定能导致明显损伤的暴露情况。将成年马来布鲁线虫雌性虫体暴露于不同浓度的FLBZ或FLBZ-R(100 nM - 10 μM)中长达五天,之后将虫体固定用于组织学检查。暴露于FLBZ后,在暴露24小时后,低至100 nM的浓度下,在皮下组织和发育中的胚胎中就明显观察到形态学损伤。结果表明,在药理学相关浓度下可实现对繁殖和生存所需组织的损伤。